A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback